摘要
目的分析我国大陆地区柯萨奇病毒A组10型(coxsackievirus A10,CV-A10)流行株基因结构及引起重症手足口病(hand,foot and mouth disease,HFMD)毒株的序列特征.方法从美国国家生物技术信息中心(National Center for Biotechnology Information,NCBI)数据库下载我国大陆地区各省份或地区不同年份的流行株序列信息,使用MEGA5.2软件构建系统进化树,应用Simplot软件进行重组分析,应用MegAlign软件对引起厦门2015年重症手足口病暴发的毒株进行比对分析.结果我国大陆地区在2010年之前曾有LineageC毒株流行,2010年之后流行的毒株均属于Lineage E,且表现为E2和E3毒株共同流行的趋势.未见已报道的CV-A10大陆流行株与其他血清型人类肠道病毒发生重组.引起不同症状的毒株在序列同源性上未见显著差异,而引起厦门2015年重症HFMD暴发的毒株在5′-UTR区128~130位点处存在3个核苷酸位点(ACT)缺失.结论应加强CV-A10的监测和流行病学研究,为CV-A10疫苗及多价HFMD疫苗的研发奠定基础.
Objective To analyze the genetic feature of the coxsackievirus A10 (CV-A10) epidemic strains in China's Mainland including the strains caused severe hand,foot,and mouth disease (HFMD) .Methods The information of epidemic strains from different provinces or regions in China's Mainland was downloaded from the National Center for Biotechnology Information (NCBI),and the phylogenetic tree was constructed using MEGA 5.2.The recombination analysis was performed by Simplot and MegAlign was applied to perform a comparative analysis with the strains causing severe HFMD outbreak in Xiamen city of China in 2015.Results The Lineage C strains circulated in China's Mainland before 2010 ; however,all epidemic strains since 2010 belonged to Lineage E,and the E2and E3strains co-circulated in the past few years.There had been no recom-bination with other serotypes of human enteroviruses (HEVs) in the reported epidemics of CV-A10strains in China's Mainland.Even though there was no significant difference in sequence homology between the strains cau-sing different symptoms,an ACT deletion existed at site 128-130in the 5′-UTR region in the strain causing se-vere HFMD outbreak in Xiamen in 2015.Conclusions Surveillance and epidemiological studies should be strengthened to lay a foundation for the research and development of CV-A10vaccine and multivalent HFMD vaccines.
作者
卞莲莲
毛群颖
高帆
吴星
孙世洋
杨晓明
梁争论
BIAN Lian-lian;GAO Fan;WU Xing;SUN Shi-yang;YANG Xiao-ming;LIANG Zheng-lun(National Institutes for Food and Drug Control,Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products,Beijing 102629,China)
出处
《中国病毒病杂志》
CAS
2018年第6期509-514,共6页
Chinese Journal of Viral Diseases
基金
“十三五”科技重大专项(2018ZX09737-011)